Analysis of Disease Free Survival and Overall Survival of HER2 Positive Subtype Breast Cancer Patients at Prof. Dr. I.G.N.G. Ngoerah Denpasar Hospital

Aim: This study aim to assess the characteristics of the patients, as well as the 3-year and 5-year overall survival and disease free survival of HER2+ breast cancer patients treated at Prof. Dr. I.G.N.G. Ngoerah Hospital Denpasar Methods: This retrospective cohort study assessed survival rates and...

Full description

Saved in:
Bibliographic Details
Main Authors: Gde Ary Putra Kamajaya, Ni Gusti Ayu Agung Manik Yuniawaty Wetan, I Gede Budhi Setiawan
Format: Article
Language:English
Published: Universitas Udayana 2025-02-01
Series:JBN (Jurnal Bedah Nasional)
Online Access:https://ojs.unud.ac.id/index.php/jbn/article/view/120383
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849722692518805504
author Gde Ary Putra Kamajaya
Ni Gusti Ayu Agung Manik Yuniawaty Wetan
I Gede Budhi Setiawan
author_facet Gde Ary Putra Kamajaya
Ni Gusti Ayu Agung Manik Yuniawaty Wetan
I Gede Budhi Setiawan
author_sort Gde Ary Putra Kamajaya
collection DOAJ
description Aim: This study aim to assess the characteristics of the patients, as well as the 3-year and 5-year overall survival and disease free survival of HER2+ breast cancer patients treated at Prof. Dr. I.G.N.G. Ngoerah Hospital Denpasar Methods: This retrospective cohort study assessed survival rates and prognostic factors among HER2+ breast cancer patients treated at Prof. Dr. I.G.N.G. Ngoerah Hospital Denpasar from January 2017 to December 2022. The study used medical records to examine variables such as age, tumor characteristics, metastasis patterns, histology, treatments, and survival outcomes over 3- and 5-year periods. Results: The 3-year survival rate was 77.7% and the 5-year survival rate was 74.3%, with median survival times of 31 months (95%CI 30.7-32.86) and 49 months (95%CI 47.85-52.089), respectively. Disease-free survival rates indicated median durations of 33 months (95%CI 32.949-34.545) at 3 years and 54 months (95% CI 53.063-56.357) at 5 years. Conclusion: This study enhances understanding of HER2+ breast cancer prognosis, emphasizing the critical roles of lymph node status, metastatic burden, and treatment strategies in determining patient outcomes.
format Article
id doaj-art-57da5ffc5acc4576b3e1b31c078764dc
institution DOAJ
issn 2548-5962
2548-981X
language English
publishDate 2025-02-01
publisher Universitas Udayana
record_format Article
series JBN (Jurnal Bedah Nasional)
spelling doaj-art-57da5ffc5acc4576b3e1b31c078764dc2025-08-20T03:11:15ZengUniversitas UdayanaJBN (Jurnal Bedah Nasional)2548-59622548-981X2025-02-01911710.24843/JBN.2025.v09.i01.p01120383Analysis of Disease Free Survival and Overall Survival of HER2 Positive Subtype Breast Cancer Patients at Prof. Dr. I.G.N.G. Ngoerah Denpasar HospitalGde Ary Putra Kamajaya0Ni Gusti Ayu Agung Manik Yuniawaty Wetan1I Gede Budhi Setiawan2General Surgery Training Program, Medical Faculty of Udayana University/Prof. Dr. I.G.N.G Ngoerah General Hospital, Denpasar, Bali, Indonesia.2 Surgical Oncology Division, Department of Surgery, Medical Faculty of Udayana University/Prof. Dr. I.G.N.G Ngoerah General Hospital, Denpasar, Bali, Indonesia.2 Surgical Oncology Division, Department of Surgery, Medical Faculty of Udayana University/Prof. Dr. I.G.N.G Ngoerah General Hospital, Denpasar, Bali, Indonesia.Aim: This study aim to assess the characteristics of the patients, as well as the 3-year and 5-year overall survival and disease free survival of HER2+ breast cancer patients treated at Prof. Dr. I.G.N.G. Ngoerah Hospital Denpasar Methods: This retrospective cohort study assessed survival rates and prognostic factors among HER2+ breast cancer patients treated at Prof. Dr. I.G.N.G. Ngoerah Hospital Denpasar from January 2017 to December 2022. The study used medical records to examine variables such as age, tumor characteristics, metastasis patterns, histology, treatments, and survival outcomes over 3- and 5-year periods. Results: The 3-year survival rate was 77.7% and the 5-year survival rate was 74.3%, with median survival times of 31 months (95%CI 30.7-32.86) and 49 months (95%CI 47.85-52.089), respectively. Disease-free survival rates indicated median durations of 33 months (95%CI 32.949-34.545) at 3 years and 54 months (95% CI 53.063-56.357) at 5 years. Conclusion: This study enhances understanding of HER2+ breast cancer prognosis, emphasizing the critical roles of lymph node status, metastatic burden, and treatment strategies in determining patient outcomes.https://ojs.unud.ac.id/index.php/jbn/article/view/120383
spellingShingle Gde Ary Putra Kamajaya
Ni Gusti Ayu Agung Manik Yuniawaty Wetan
I Gede Budhi Setiawan
Analysis of Disease Free Survival and Overall Survival of HER2 Positive Subtype Breast Cancer Patients at Prof. Dr. I.G.N.G. Ngoerah Denpasar Hospital
JBN (Jurnal Bedah Nasional)
title Analysis of Disease Free Survival and Overall Survival of HER2 Positive Subtype Breast Cancer Patients at Prof. Dr. I.G.N.G. Ngoerah Denpasar Hospital
title_full Analysis of Disease Free Survival and Overall Survival of HER2 Positive Subtype Breast Cancer Patients at Prof. Dr. I.G.N.G. Ngoerah Denpasar Hospital
title_fullStr Analysis of Disease Free Survival and Overall Survival of HER2 Positive Subtype Breast Cancer Patients at Prof. Dr. I.G.N.G. Ngoerah Denpasar Hospital
title_full_unstemmed Analysis of Disease Free Survival and Overall Survival of HER2 Positive Subtype Breast Cancer Patients at Prof. Dr. I.G.N.G. Ngoerah Denpasar Hospital
title_short Analysis of Disease Free Survival and Overall Survival of HER2 Positive Subtype Breast Cancer Patients at Prof. Dr. I.G.N.G. Ngoerah Denpasar Hospital
title_sort analysis of disease free survival and overall survival of her2 positive subtype breast cancer patients at prof dr i g n g ngoerah denpasar hospital
url https://ojs.unud.ac.id/index.php/jbn/article/view/120383
work_keys_str_mv AT gdearyputrakamajaya analysisofdiseasefreesurvivalandoverallsurvivalofher2positivesubtypebreastcancerpatientsatprofdrigngngoerahdenpasarhospital
AT nigustiayuagungmanikyuniawatywetan analysisofdiseasefreesurvivalandoverallsurvivalofher2positivesubtypebreastcancerpatientsatprofdrigngngoerahdenpasarhospital
AT igedebudhisetiawan analysisofdiseasefreesurvivalandoverallsurvivalofher2positivesubtypebreastcancerpatientsatprofdrigngngoerahdenpasarhospital